Hamed Emami1, Parmanand Singh1, Megan MacNabb1, Esad Vucic1, Zachary Lavender1, James H F Rudd2, Zahi A Fayad3, Joshua Lehrer-Graiwer4, Magnus Korsgren5, Amparo L Figueroa1, Jill Fredrickson4, Barry Rubin6, Udo Hoffmann1, Quynh A Truong1, James K Min7, Amos Baruch4, Khurram Nasir8, Matthias Nahrendorf9, Ahmed Tawakol10. 1. Cardiac MR PET CT Program, Division of Cardiac Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 2. Division of Cardiovascular Medicine, University of Cambridge, Cambridge, United Kingdom. 3. Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York. 4. Genentech, San Francisco, California. 5. BioInvent International AB, Lund, Sweden. 6. Division of Vascular Surgery, Peter Munk Cardiac Centre, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada. 7. Departments of Radiology and Medicine, Weill Cornell Medical College and the New York-Presbyterian Hospital, New York, New York. 8. Baptist Health South Florida, Miami, Florida. 9. Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 10. Cardiac MR PET CT Program, Division of Cardiac Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; Division of Cardiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: atawakol@partners.org.
Abstract
OBJECTIVES: This study sought to determine whether splenic activation after acute coronary syndrome (ACS) is linked to leukocyte proinflammatory remodeling and whether splenic activity independently predicts the risk of cardiovascular disease (CVD) events. BACKGROUND: Pre-clinical data suggest the existence of a cardiosplenic axis, wherein activation of hematopoietic tissues (notably in the spleen) results in liberation of proinflammatory leukocytes and accelerated atherosclerotic inflammation. However, it is presently unknown whether a cardiosplenic axis exists in humans and whether splenic activation relates to CVD risk. METHODS: (18)F-fluorodeoxyglucose ((18)FDG)-positron emission tomography (PET) imaging was performed in 508 individuals across 2 studies. In the first study, we performed FDG-PET imaging in 22 patients with recent ACS and 22 control subjects. FDG uptake was measured in spleen and arterial wall, whereas proinflammatory gene expression of circulating leukocytes was assessed by quantitative real-time polymerase chain reaction. In a second study, we examined the relationship between splenic tissue FDG uptake with subsequent CVD events during follow-up (median 4 years) in 464 patients who previously had undergone FDG-PET imaging. RESULTS: Splenic activity increased after ACS and was significantly associated with multiple indices of inflammation: 1) up-regulated gene expression of proinflammatory leukocytes; 2) increased C-reactive protein; and 3) increased arterial wall inflammation (FDG uptake). Moreover, in the second study, splenic activity (greater than or equal to the median) was associated with an increased risk of CVD events (hazard ratio [HR]: 3.3; 95% confidence interval [CI]: 1.5 to 7.3; p = 0.003), which remained significant after adjustment for CVD risk factors (HR: 2.26; 95% CI: 1.01 to 5.06; p = 0.04) and for arterial FDG uptake (HR: 2.68; 95% CI: 1.5 to 7.4; p = 0.02). CONCLUSIONS: Our findings demonstrate increased splenic metabolic activity after ACS and its association with proinflammatory remodeling of circulating leukocytes. Moreover, we observed that metabolic activity of the spleen independently predicted risk of subsequent CVD events. Collectively, these findings provide evidence of a cardiosplenic axis in humans similar to that shown in pre-clinical studies.
OBJECTIVES: This study sought to determine whether splenic activation after acute coronary syndrome (ACS) is linked to leukocyte proinflammatory remodeling and whether splenic activity independently predicts the risk of cardiovascular disease (CVD) events. BACKGROUND: Pre-clinical data suggest the existence of a cardiosplenic axis, wherein activation of hematopoietic tissues (notably in the spleen) results in liberation of proinflammatory leukocytes and accelerated atherosclerotic inflammation. However, it is presently unknown whether a cardiosplenic axis exists in humans and whether splenic activation relates to CVD risk. METHODS: (18)F-fluorodeoxyglucose ((18)FDG)-positron emission tomography (PET) imaging was performed in 508 individuals across 2 studies. In the first study, we performed FDG-PET imaging in 22 patients with recent ACS and 22 control subjects. FDG uptake was measured in spleen and arterial wall, whereas proinflammatory gene expression of circulating leukocytes was assessed by quantitative real-time polymerase chain reaction. In a second study, we examined the relationship between splenic tissue FDG uptake with subsequent CVD events during follow-up (median 4 years) in 464 patients who previously had undergone FDG-PET imaging. RESULTS: Splenic activity increased after ACS and was significantly associated with multiple indices of inflammation: 1) up-regulated gene expression of proinflammatory leukocytes; 2) increased C-reactive protein; and 3) increased arterial wall inflammation (FDG uptake). Moreover, in the second study, splenic activity (greater than or equal to the median) was associated with an increased risk of CVD events (hazard ratio [HR]: 3.3; 95% confidence interval [CI]: 1.5 to 7.3; p = 0.003), which remained significant after adjustment for CVD risk factors (HR: 2.26; 95% CI: 1.01 to 5.06; p = 0.04) and for arterial FDG uptake (HR: 2.68; 95% CI: 1.5 to 7.4; p = 0.02). CONCLUSIONS: Our findings demonstrate increased splenic metabolic activity after ACS and its association with proinflammatory remodeling of circulating leukocytes. Moreover, we observed that metabolic activity of the spleen independently predicted risk of subsequent CVD events. Collectively, these findings provide evidence of a cardiosplenic axis in humans similar to that shown in pre-clinical studies.
Authors: Jens Jakob Thune; James E Signorovitch; Lars Kober; John J V McMurray; Karl Swedberg; Jean Rouleau; Aldo Maggioni; Eric Velazquez; Robert Califf; Marc A Pfeffer; Scott D Solomon Journal: Eur J Heart Fail Date: 2010-10-29 Impact factor: 15.534
Authors: Francois Jamar; John Buscombe; Arturo Chiti; Paul E Christian; Dominique Delbeke; Kevin J Donohoe; Ora Israel; Josep Martin-Comin; Alberto Signore Journal: J Nucl Med Date: 2013-01-28 Impact factor: 10.057
Authors: James H F Rudd; Jagat Narula; H William Strauss; Renu Virmani; Josef Machac; Mike Klimas; Nobuhiro Tahara; Valentin Fuster; Elizabeth A Warburton; Zahi A Fayad; Ahmed A Tawakol Journal: J Am Coll Cardiol Date: 2010-06-08 Impact factor: 24.094
Authors: Anja M van der Laan; Ellis N Ter Horst; Ronak Delewi; Mark P V Begieneman; Paul A J Krijnen; Alexander Hirsch; Mehrdad Lavaei; Matthias Nahrendorf; Anton J Horrevoets; Hans W M Niessen; Jan J Piek Journal: Eur Heart J Date: 2013-08-21 Impact factor: 29.983
Authors: Didier Lardinois; Walter Weder; Thomas F Hany; Ehab M Kamel; Stephan Korom; Burkhardt Seifert; Gustav K von Schulthess; Hans C Steinert Journal: N Engl J Med Date: 2003-06-19 Impact factor: 91.245
Authors: Vasundhara Kain; Kevin A Ingle; Romain A Colas; Jesmond Dalli; Sumanth D Prabhu; Charles N Serhan; Medha Joshi; Ganesh V Halade Journal: J Mol Cell Cardiol Date: 2015-04-11 Impact factor: 5.000
Authors: Amr Alaarg; Carlos Pérez-Medina; Josbert M Metselaar; Matthias Nahrendorf; Zahi A Fayad; Gert Storm; Willem J M Mulder Journal: Adv Drug Deliv Rev Date: 2017-05-12 Impact factor: 15.470
Authors: Ahmed Tawakol; Amorina Ishai; Danny Li; Richard A P Takx; Sophia Hur; Yannick Kaiser; Miguel Pampaloni; Adam Rupert; Denise Hsu; Irini Sereti; Rémi Fromentin; Nicolas Chomont; Peter Ganz; Steven G Deeks; Priscilla Y Hsue Journal: JAMA Cardiol Date: 2017-02-01 Impact factor: 14.676
Authors: Vincent Sarrazy; Manon Viaud; Marit Westerterp; Stoyan Ivanov; Sophie Giorgetti-Peraldi; Rodolphe Guinamard; Emmanuel L Gautier; Edward B Thorp; Darryl C De Vivo; Laurent Yvan-Charvet Journal: Circ Res Date: 2016-02-29 Impact factor: 17.367
Authors: Daniel B McKim; Wenyuan Yin; Yufen Wang; Steve W Cole; Jonathan P Godbout; John F Sheridan Journal: Cell Rep Date: 2018-11-27 Impact factor: 9.423
Authors: Helmut Raphael Lieder; Petra Kleinbongard; Andreas Skyschally; Helene Hagelschuer; William M Chilian; Gerd Heusch Journal: Circ Res Date: 2018-10-26 Impact factor: 17.367
Authors: Hendrik B Sager; Maarten Hulsmans; Kory J Lavine; Marina B Moreira; Timo Heidt; Gabriel Courties; Yuan Sun; Yoshiko Iwamoto; Benoit Tricot; Omar F Khan; James E Dahlman; Anna Borodovsky; Kevin Fitzgerald; Daniel G Anderson; Ralph Weissleder; Peter Libby; Filip K Swirski; Matthias Nahrendorf Journal: Circ Res Date: 2016-07-21 Impact factor: 17.367
Authors: Chris T Longenecker; Claire E Sullivan; Justin Morrison; Corrilynn O Hileman; David A Zidar; Robert Gilkeson; James O'Donnell; Grace A McComsey Journal: AIDS Date: 2018-01-02 Impact factor: 4.177